Overview of Ursolin

Property	Description
Active ingredient	Ursodeoxycholic acid (UDCA)
Form	Oral dosage form (Hard capsules or tablets)
Pharmacological class	Cholelitholytic agent and Hepatoprotective agent
Common purpose	Modulating bile composition and protecting liver cells
Origin	Chemically synthesized bile acid derivative

What Type of Medicine is Ursolin (Ursodiol)?

Ursolin is a pharmaceutical preparation whose core therapeutic substance is Ursodeoxycholic acid (UDCA), classified primarily as a cholelitholytic agent and a hepatoprotective agent. This medicine is designated as a single-ingredient product and is typically prescribed, focusing on its specialized utility in gastroenterology and hepatology. UDCA is structurally defined as a bile acid derivative. The compound's function in reducing cholesterol content in bile is noted in pharmacological studies.

The pharmacological classification as a cholelitholytic agent identifies its action in reducing and dissolving solid particles in bile. Its hepatoprotective status signifies its capacity to stabilize and protect liver cells (hepatocytes) from damage, an effect clinically recognized for its long-term benefits in managing specific biliary conditions.

Composition and Origin: Is Ursodiol a Natural Substance?

While Ursodeoxycholic acid is a naturally occurring bile acid present in human bile, the substance used in commercial Ursolin is produced through chemical synthesis to achieve the necessary high purity and consistent potency. Ursolin is supplied as an oral dosage form, most commonly in the presentation of hard capsules or tablets. These preparations contain the active ingredient along with minimal pharmaceutical excipients to facilitate absorption. UDCA is utilized for the modification of bile composition within the body.

What is the General Purpose of Ursodiol?

The general purpose of Ursodiol is to support the healthy function of the biliary system by modulating the chemical composition of bile. This modulation results in two high-level general benefits: the ability to reduce cholesterol saturation (promoting the dissolution of cholesterol particles) and the capacity to provide cytoprotection (cell protection) to liver cells. A typical neutral use scenario for UDCA involves situations where the bile is overly saturated with cholesterol, confirming its unique role as an agent that directly adjusts the chemical environment of the bile.

Regulatory References

What side effects are possible with Ursolin?

Possible Side Effects and Safety Information

The safety profile for Ursolin (ursodiol) is based on data collected from clinical trials and post-marketing surveillance, as documented by official regulatory sources (e.g., FDA, EMA). Side effects are classified by the frequency of their occurrence and the body system they affect.

Frequency-Classified Adverse Reactions

Classification	Examples of Documented Adverse Reactions
Very Common (occurs in 10% or more)	Diarrhea, Abdominal pain, Nausea, Vomiting
Common (occurs in 1% to less than 10%)	Constipation, Alopecia (hair loss), Rash, Pruritus (itching), Dizziness, Fatigue
Very Rare (occurs in less than 0.01%)	Calcification of gallstones, Decompensation of hepatic cirrhosis, Enteroliths (bezoars)

Serious Adverse Reactions and Key Safety Constraints

Regulatory documents list certain serious adverse reactions, which, while rare, are clinically significant. These include the potential for decompensation of hepatic cirrhosis, especially in pre-existing conditions, and the calcification of gallstones, which may require surgical intervention.

Safety-related restrictions state that Ursolin must not be used (is contraindicated) in patients with conditions such as radio-opaque calcified gallstones, acute inflammation of the gallbladder (cholecystitis), or a non-functioning gallbladder.

Safety Monitoring: Official prescribing information requires patients to undergo regular monitoring of liver function tests (e.g., ALT, AST, gamma-GT), particularly during the first three months of treatment, and periodically thereafter. This requirement addresses the potential for temporary changes in liver enzyme levels or the rare risk of worsening pre-existing liver conditions. Specific caution and safety statements also apply to use during pregnancy and lactation, and in patients with hepatic impairment.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The primary sign of Ursodeoxycholic acid (Ursolin) overexposure documented in official regulatory labeling is the onset of severe, watery diarrhea and related gastrointestinal disturbances, often accompanied by abdominal pain. This is the main documented clinical manifestation in cases of high-dose ingestion.

High-dose overexposure may lead to serious systemic consequences defined by the resulting fluid loss. These severe outcomes include dehydration, which can progress to critical electrolyte imbalances such as hypokalaemia (low potassium) and metabolic acidosis. The severity of the overdose is directly classified by the extent of this fluid and electrolyte depletion, which requires urgent medical care.

Emergency Actions Mandated by Regulators

In the event of suspected Ursolin overdose, regulatory documents state the immediate necessity to seek emergency medical attention or contact a poison control center. This action is critical due to the potential for severe fluid and electrolyte loss.

No specific antidote is known for Ursodeoxycholic acid. Therefore, the management mandated by official labeling is strictly symptomatic and supportive treatment. Medical intervention must focus on the urgent correction of fluid and electrolyte imbalance to stabilize the patient and prevent life-threatening complications. Continuous monitoring, particularly of electrolytes and fluid status, may be required in a hospital setting.

Therapeutic Uses of Ursolin

What Ursolin treats: main uses and benefits

Ursolin contains ursodeoxycholic acid, a naturally occurring bile acid found in small quantities in human bile. It is primarily used to manage conditions affecting the liver and the gallbladder by modifying the composition of bile and protecting liver cells from damage.

Dissolution of Cholesterol Gallstones

One of the primary uses of Ursolin is the dissolution of gallstones caused by excess cholesterol. When bile contains too much cholesterol and insufficient bile salts, the cholesterol can crystallize into stones.

Mechanism: It works by reducing the amount of cholesterol secreted into the bile and by dispersing the cholesterol from existing stones, gradually dissolving them.
Criteria: This application is typically reserved for patients with radiolucent (non-calcified) gallstones in a gallbladder that still functions normally.

Primary Biliary Cholangitis (PBC)

Ursolin is a standard treatment for Primary Biliary Cholangitis, a chronic disease where the bile ducts in the liver are slowly destroyed. When bile ducts are damaged, bile can build up in the liver (cholestasis), leading to tissue scarring.

Liver Protection: The medication helps by replacing more toxic, hydrophobic bile acids that can damage liver cell membranes with ursodeoxycholic acid, which is cytoprotective.
Symptom Management: It is used to improve liver function markers and may help slow the progression of the disease to more advanced stages.

Hepatobiliary Disorders in Pediatric Populations

In specific pediatric cases, Ursolin is used to manage hepatobiliary disorders associated with cystic fibrosis. It helps improve bile flow and supports liver function in children and adolescents affected by bile duct complications related to the underlying genetic condition.

Summary of Benefits

The therapeutic benefits of Ursolin focus on improving the flow of bile and changing its chemical balance. By neutralizing the inflammatory effects of more aggressive bile acids, it serves as a stabilizer for the liver's metabolic environment and helps maintain the integrity of the biliary system.

Regulatory References

NIH MedlinePlus Drug Information on Ursodiol

Eligibility and Restrictions for Use

The eligibility for using Ursolin (ursodeoxycholic acid) is strictly defined by regulatory authorities and depends on a patient's clinical status and comorbidities.

Contraindications: When Use is Prohibited

Ursolin is contraindicated and must not be used in patients with the following conditions, as stated in official prescribing information:

Biliary Obstruction: Complete occlusion of the biliary tract (bile duct blockage) or acute inflammation of the gallbladder or bile ducts.
Gallstone Type: Presence of radio-opaque, calcified gallstones (the medicine is ineffective for these).
Organ Function: Advanced stage of primary biliary cirrhosis (decompensated cirrhosis) or impaired gallbladder contractility.
Other Conditions: Known hypersensitivity to the drug's components, or experiencing frequent episodes of biliary colic.

Age and Specific Populations

Population	Eligibility Status (Regulatory)
Adults	Use is established for primary biliary cholangitis and certain cholesterol gallstones.
Children (Ages 6–18)	Use is established specifically for hepatobiliary disorder associated with Cystic Fibrosis.
General Pediatric Use	Safety and efficacy are not established for general use in this population.
Older Adults	No specific restrictions, but caution is advised due to potential for increased sensitivity.

Pregnancy and Reproductive Status

Pregnancy: Use is generally contraindicated unless clearly necessary; pregnancy must be excluded before starting therapy in certain regions.
Lactation: Use is generally not recommended during breastfeeding.
Contraception: Women of childbearing potential are required to use reliable non-hormonal contraception during therapy.

Eligibility criteria may vary by region; this information reflects common constraints documented by major governmental regulatory bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for ursodeoxycholic acid (Ursolin) primarily addresses interference with absorption, changes to drug plasma levels, and counteracting pharmacodynamic effects, as outlined in official regulatory information.

Interactions Requiring Dose Separation:

Interacting Substance Category	Interaction Mechanism	Practical Requirement
Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol)	Bind Ursolin in the intestine, reducing absorption and efficacy.	Must be taken at least 2 hours before or after Ursolin.
Aluminum-Containing Antacids	Bind Ursolin in the intestine, reducing absorption and efficacy.	Must be taken at least 2 hours before or after Ursolin.

Interactions Affecting Drug Exposure:

Ursolin has been documented to affect the plasma concentrations of certain co-administered medicines. The label notes that Ursolin can increase the absorption of ciclosporin, requiring therapeutic drug monitoring and dose adjustment. Conversely, due to presumed induction of the CYP3A4 enzyme, Ursolin may reduce the plasma concentrations of certain CYP3A4 substrates, such as nitrendipine and dapsone, potentially reducing their effect.

Interactions Counteracting Efficacy:

Certain agents that increase cholesterol secretion, including oestrogens, oral contraceptives, and lipid-lowering agents like clofibrate, may counteract the intended therapeutic effects of Ursolin and are generally advised to be avoided.

Mechanism of Action

How Ursolin Works

The action of Ursolin (Ursodeoxycholic acid or UDCA) is based on a multifaceted mechanism that influences both the physical chemistry of bile and the cellular health of the liver.

Physicochemical Modulation of Bile and Cholesterol Homeostasis

This core mechanism involves Ursolin's role as a more hydrophilic bile acid, which acts by diluting the existing bile acid pool and competitively inhibiting the intestinal absorption and hepatic secretion of cholesterol into the bile. This action fundamentally shifts the chemical balance, reducing the bile's cholesterol saturation index. The resulting physiological effect is a more soluble environment that discourages the formation of cholesterol-rich solid particles.

Cytoprotection and Anti-Apoptotic Signaling

Ursolin initiates direct cellular stabilization, integrating into the hepatocyte and cholangiocyte membranes to increase membrane resistance to the effects of highly toxic endogenous bile acids. At the molecular level, it inhibits the function of the Mitochondrial Permeability Transition Pore (MPTP), thereby blocking the cascade of events that leads to apoptosis (programmed cell death). This mechanism maintains the structural integrity of the liver cells by blocking apoptotic signaling.

Choleretic Action via Transport Upregulation

This domain addresses the drug's influence on bile flow. Ursolin modulates key canalicular transporters, notably stimulating the activity of the Bile Salt Export Pump (BSEP) and the Chloride-Bicarbonate Anion Exchanger (AE2). This results in the increased secretion of bile salts and bicarbonate-rich fluid, promoting a greater volume of bile flow. The ensuing physiological effect facilitates the clearance of accumulated bile acids from the liver and contributes to the excretory function of the biliary system.

Dosage and Administration Information

How Ursolin (Ursodeoxycholic Acid) is Used

Ursolin is administered via the oral route only, primarily in the form of capsules or film-coated tablets, with the total daily amount typically split into multiple portions. The medicine’s usage is fundamentally structured by weight-based dosing and mandatory timing instructions specified for the medication.

For chronic conditions such as Primary Biliary Cholangitis (PBC), the standard regimen is 13 to 15 mg per kilogram of body weight per day, divided into two to four daily doses. For the dissolution of cholesterol gallstones, a lower weight-based range of 8 to 10 mg/kg/day is usually applied.

Administration Requirements

Instruction	Detail
Timing with Food	Administration is required with food (during or immediately after meals) to optimize the absorption of the active ingredient.
Dosing Frequency	The total daily dose must be administered in divided doses (typically two to four times daily) rather than as a single dose.
Handling	Capsules and tablets must be swallowed whole with liquid and should not be crushed or chewed due to the bitter taste. Scored tablets may be broken in half to achieve the correct dose.
Missed Dose	If a dose is missed, it should be taken as soon as it is remembered unless it is near the time of the next scheduled dose, in which case the missed dose must be skipped (doses must not be doubled).
Duration	Therapy for PBC is generally considered a long-term, chronic course. Treatment for gallstone dissolution is extended, potentially lasting up to two years, and must continue for three to four months after stones are no longer visible.

This protocol ensures consistent intake and adherence to standard usage patterns.

Recent Clinical Evidence

Research evidence / Overview of studies for Ursolin

Evidence Supporting Use in Primary Biliary Cholangitis (PBC)

The research on Ursolin for Primary Biliary Cholangitis (PBC) has involved both short-term Randomized Controlled Trials (RCTs) and subsequent long-term observational follow-up studies. Researchers examined hard clinical outcomes like the period before the need for a liver transplant or death, as well as short-term changes in biomarkers, such as Alkaline Phosphatase (ALP) and bilirubin levels, in adults with PBC.

Long-term follow-up and registry analyses examined the relationship between Ursolin use and the period before the need for a liver transplant or death in specific patient groups. Studies also reported patterns of change in the biochemical marker levels in the observed populations during the study period. Initial RCTs often had limited sample sizes, leading to reliance on registry data for long-term survival analysis. Data for certain aspects, such as the durable impact on quality of life, are still emerging.

Evidence Supporting Use for Cholesterol Gallstone Dissolution

The evidence for cholesterol gallstone dissolution is built upon controlled trials and RCTs that explored how Ursolin was observed in non-calcified gallstones in adults with a functioning gallbladder. The main research focus was the complete dissolution rate and changes in the cholesterol saturation of the bile. Studies reported patterns of bile that were less saturated with cholesterol, measured during periods of Ursodiol use. Findings indicated that complete dissolution was not observed in all participants and was highly dependent on the stone’s initial size and composition.

What remains uncertain is the risk of gallstone recurrence after successful dissolution is achieved and treatment is stopped, as long-term effects are not fully established in this context. Furthermore, research findings indicate extended periods of use were required in the trials.

Evidence in Special Patient Groups

Studies have evaluated the use of Ursolin in Intrahepatic Cholestasis of Pregnancy (ICP) and Cystic Fibrosis-Associated Liver Disease (CFLD).

For ICP, RCTs and systematic reviews monitored maternal outcomes (pruritus and serum bile acid concentrations) and composite perinatal outcomes. Findings were mixed regarding the prevention of severe perinatal outcomes, and some large RCTs reported patterns that did not establish a statistically significant association with a reduction in these critical fetal outcomes. For CFLD, the evidence is primarily from a mix of limited small RCTs and long-term cohort studies. Research examined changes in liver enzymes, but the evidence quality varies, and systematic reviews often classify the available research as generally being of very low quality.

Frequently Asked Questions (FAQ)

Common questions about Ursolin (FAQ)

Q: Can Ursolin cause stomach issues like nausea or diarrhea?

Official product information indicates that gastrointestinal issues are known to occur. Diarrhea and abdominal pain are listed as very common side effects, affecting 10% or more of patients. Nausea and vomiting are also documented as known side effects.

Q: What should I do if my side effects from Ursolin seem to be getting worse?

Regulatory guidance indicates that patients should seek advice from their prescribing doctor if side effects persist or worsen. This is generally advised for any concerning symptoms, including severe or persistent changes in stool consistency, which can sometimes occur.

Q: How quickly should I expect to see the effects of Ursolin?

The time it takes to see evidence of the therapeutic effect varies by condition. For chronic liver conditions, improvement is often assessed by monitoring biochemical markers, such as liver function tests, over a period that typically ranges from three to six months. Complete gallstone dissolution, if applicable, can require up to two years of treatment.

Q: Are there common signs that Ursolin is starting to work?

Improvement is primarily assessed by a healthcare professional through objective measures. These include the results of regular blood tests that monitor liver function (ALT, AST, ALP). Some patients may also notice an improvement in symptoms like pruritus (itching) associated with their underlying condition.

Q: Is it normal to feel a bit tired when first starting Ursolin?

Yes, official regulatory documents list both fatigue (feeling tired) and dizziness as common adverse reactions. This indicates that these effects are known to occur in a small percentage of patients (1% to less than 10%) and may be experienced when starting the medication.

Q: Is there a best time of day to take Ursolin for maximum benefit?

Official administration instructions require that the total daily dose be split into divided doses and taken with food. While this ensures consistent intake, some clinical reports note that taking the last dose of the day at bedtime is often practiced, especially when the goal is gallstone dissolution.

Q: Is Ursolin safe to use long-term?

The treatment is classified as a long-term, chronic course for specific conditions such as Primary Biliary Cholangitis (PBC). When used long-term, the medication should always be taken under the direct supervision and monitoring of a healthcare professional.

Q: Can older adults safely use Ursolin?

Official guidance indicates that no specific restrictions for use in older adults are listed. However, caution is generally advised for older patients due to the potential for increased sensitivity to medications, and monitoring by a healthcare provider is essential.

Q: What kind of research supports the use of Ursolin?

The use of Ursolin has been evaluated in clinical studies that observed its effects on specific conditions. For example, research for Primary Biliary Cholangitis examined long-term outcomes, such as liver transplant-free survival, and tracked changes in liver biomarkers like Alkaline Phosphatase (ALP).

Q: Can children or teenagers take Ursolin for certain conditions?

Use of Ursolin is established by regulatory bodies for children and teenagers aged 6 to 18 years, but only for the treatment of hepatobiliary disorder associated with Cystic Fibrosis. Safety and effectiveness for general pediatric use beyond this specific indication are not established in official labeling.

Q: Does Ursolin interact with blood thinners?

Official regulatory documents indicate that Ursolin may affect the absorption of certain medications. Therefore, taking it alongside blood thinners (anticoagulants) may necessitate careful monitoring and dose review by a healthcare provider.

Q: Can taking Ursolin affect the results of a routine physical or lab work?

Yes, regulatory guidelines require that the drug's effect be assessed by regular monitoring of liver function tests (e.g., ALT, AST, and gamma-GT). It is important to inform your healthcare provider that you are taking Ursolin before any lab work.

Q: Does Ursolin impact fertility or reproductive health?

For women of childbearing potential, official prescribing information advises the use of reliable non-hormonal contraception during therapy. This requirement is noted in prescribing information for reproductive safety.

Q: What happens if I accidentally take two doses of Ursolin close together?

While regulatory guidance is focused on missed doses, a single, accidental extra dose is generally not expected to cause significant harm. However, taking a much higher dose than prescribed may result in symptoms such as severe diarrhea, and patients should contact their doctor if this occurs.

Q: How effective is Ursolin for preventing gallstone recurrence?

Ursolin is used to dissolve existing cholesterol gallstones, but the risk of recurrence after successful treatment is not fully established. Clinical study summaries note that this uncertainty remains once treatment is stopped.

Q: Are there any known allergic reactions to Ursolin?

The medication is contraindicated (should not be used) in patients who have a known hypersensitivity to the active substance or to any of the other components (excipients) in the product. Hypersensitivity refers to a known allergic or immune response.

How should Ursolin be stored and disposed of?

How to Store and Dispose of Ursolin?

This section details the officially documented requirements for the storage and disposal of Ursolin (ursodeoxycholic acid) oral dosage forms, based strictly on government regulatory labeling.

Requirement Area	Official Regulatory Rule
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Handling	Keep the medicine away from moisture, direct light, and excessive heat. It is mandatory not to freeze the product.
Container & Stability	Store in a tightly closed container. Scored half-tablets must be stored separately and remain stable for use for up to 28 days.
Child Safety	Mandatory instruction to keep out of the reach of children.
Disposal	All outdated or no longer needed medicine must be discarded. Consult a healthcare professional (pharmacist) for guidance on proper disposal, avoiding flushing down the toilet or placing in household trash unless otherwise instructed.

These rules define the required environment—a dry, temperature-controlled, dark space—and mandate specific packaging integrity. Disposal requires following official pharmaceutical waste channels for the safe discarding of all unused product.

Ursolin